{
  "id": 16577676,
  "title": "Zhejiang Wenda Pharma reports Phase II BET inhibitor trial data",
  "url": "https://urgent.news/2026/10/26/zhejiang-wenda-pharma-reports-phase-ii-bet-inhibitor-trial-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T08:57:30.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/zhejiang-wenda-pharma-reports-phase-ii-bet-inhibitor-trial-data-163660.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Zhejiang Wenda Pharma is set to present phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, at the 2026 ESMO Annual Meeting. The study, conducted in Chinese patients with advanced NUT carcinoma (NC), revealed a 30% objective response rate (ORR) and a 47.5% disease control rate (DCR). The trial also showed median progression-free survival (PFS) and overall survival (OS) of 2.76 and 9.33 months, respectively. NHWD-870 HCl, a novel oral BET inhibitor, has been granted breakthrough therapy designation by the China National Medical Products Administration (NMPA) for advanced thoracic NUT carcinoma.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}